Conference Correspondent

PREAMBLE: Real-World Efficacy Analyses in Multiple Myeloma Patients with One Line of Prior Therapy

Conference Correspondent - Conference Correspondent, ASH 2016 - Multiple Myeloma

Although several treatment options for multiple myeloma (MM) have become available in recent years, there has been a paucity of data on real-world treatment outcomes associated with these treatments. PREAMBLE (Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation; NCT01838512), a multinational observational study, seeks to address this evidence gap by assessing the impact of prior transplantation experience on real-world clinical effectiveness of immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs), and combination therapy for relapsed/refractory MM (RRMM). The results of preliminary efficacy analyses were reported at the ASH 2016 Annual Meeting.

This analysis included patients with a confirmed diagnosis of RRMM with 1 prior treatment who started treatment with an IMiD, PI, or IMiD+PI 90 days prior/30 days following study enrollment. Response rate, time in response, progression-free survival (PFS), and overall survival (OS) were evaluated from patient data collected at each healthcare provider visit for a follow-up period of 3 years. Of 924 enrolled and treated patients, 395 (43%) had 1 prior line of therapy (median age, 70 years; 56% male) with an IMiD (n = 208), a PI (n = 156), or IMiD+PI (n = 31). Median follow-up was 19 months, and 229 remained on study. The primary reason for discontinuation was death due to disease progression; no deaths were due to drug toxicity. Approximately 30% had prior transplantation experience. In patients without transplantation experience (n = 257; 65%), the response rate was similar between patients with (43%) and without prior transplantation experience (46%). Overall, the median time in response was 21 months in patients with prior transplantation versus 16 months in those without prior transplantation. Patients receiving an IMiD as index therapy had better outcomes than patients receiving PI, regardless of prior transplantation status. OS rate at 12 months was similar regardless of prior transplantation status.

Researchers observed loss of response over time, highlighting the continuing unmet medical need in RRMM, regardless of index therapy type or prior transplantation experience. Collectively, the data underscore the importance of novel therapies that can provide durable responses and improve treatment outcomes for patients with RRMM. The PREAMBLE study is ongoing, and additional findings will be reported in the future.

Durie B, et al. ASH 2016. Abstract 2403.

Related Items
Sustained Response Following Discontinuation of MTX in Subcutaneous Tocilizumab-Treated Patients with RA
Conference Correspondent published on November 9, 2017 in ACR 2017, Conference Correspondent
Longer Duration of Response in MOBILITY Study with Sarilumab plus MTX in Patients with Active, Moderate-to-Severe RA
Conference Correspondent published on November 9, 2017 in ACR 2017, Conference Correspondent
Improvements in Remission and Low Disease Activity Achieved with Ongoing Sarilumab Treatment in Patients with RA
Conference Correspondent published on November 9, 2017 in ACR 2017, Conference Correspondent
Efficacy and Safety of Switching from Adalimumab to Sarilumab in Open-Label Extension of MONARCH Trial in Patients with Active RA
Conference Correspondent published on November 9, 2017 in ACR 2017, Conference Correspondent
Improvements in PROs with Tofacitinib with and without MTX versus Adalimumab with MTX for the Treatment of RA
Conference Correspondent published on November 9, 2017 in ACR 2017, Conference Correspondent
Last modified: May 17, 2017
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • Lynx CME